EVolution Therapeutics is delighted to announce that we have joined the 2026 Accelerate@Babraham cohort.
Supporting early-stage life science innovation
Accelerate@Babraham is one of the UK’s leading life science accelerators. It helps early-stage companies strengthen their science, shape their commercial strategy and prepare for investment and growth.
The programme offers expert mentoring, investor support, laboratory space and access to the wider Babraham Research Campus ecosystem. This includes more than 60 companies, 2,000 employees and 300 academic researchers.
A pivotal moment for EVolution Therapeutics
Joining the cohort comes at an important time for EVolution Therapeutics. We are currently raising pre-seed funding to advance our mRNA therapeutic platform towards IND-enabling studies.
Our platform is built around resolution biology. This means harnessing the body’s natural pathways to actively resolve dysregulated inflammation.
Our first focus is wound healing. However, we believe the platform has potential across a much broader range of inflammatory diseases.
Building within a world-leading bioscience ecosystem
Dr James Gavin, CEO and Co-founder of EVolution Therapeutics, said:
“I couldn’t believe it when we got accepted. It’s one of the most comprehensive accelerators around. Although it was our top target, we never expected to secure a place.
Having access to the Cambridge biosciences network is hugely valuable. The peer network of startups here at Babraham Research Campus is also a major advantage.
For therapeutics, this is the place to be. It is a premier location for translating biological technologies, with a world-leading institute at its heart. We’re incredibly excited to be part of the community here.”
Looking ahead
We are proud to join an exciting cohort alongside BASE Rx, Elarna Bio, Ribogenyx, Semper-B Therapeutics and Switch Biologics.
We would like to thank the Accelerate@Babraham team for this opportunity. We look forward to making the most of the programme as we continue to develop next-generation mRNA therapeutics for inflammatory disease.
Investors interested in mRNA therapeutics, inflammation resolution and regenerative medicine are encouraged to get in touch with the EVolution Therapeutics team.
